Log In
Print
BCIQ
Print
Print this Print this
 

rocilinostat (ACY-1215)

  Manage Alerts
Collapse Summary General Information
Company Acetylon Pharmaceuticals Inc.
DescriptionOral selective histone deacetylase 6 (HDAC6) inhibitor
Molecular Target Histone deacetylase 6 (HDAC6)
Mechanism of ActionHistone deacetylase 6 (HDAC6) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I/II
Standard IndicationMultiple myeloma (MM)
Indication DetailsTreat multiple myeloma (MM); Treat relapsed or refractory multiple myeloma (MM)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today